Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Inventiva S.A. (IVA)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
13.30+0.20 (+1.49%)
At close: 03:51PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.10
Open13.30
Bid13.30 x 1200
Ask15.71 x 1300
Day's Range13.18 - 13.30
52 Week Range10.52 - 19.06
Volume988
Avg. Volume40,217
Market Cap519.634M
Beta (5Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Inventiva reports 2021 Third Quarter Financial Information

    Cash and cash equivalents at €105.7m as of September 30, 2021Revenues of €0.2m for the first nine months of 2021 Daix (France), Long Island City (New York, United States), November 10, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today reported it

  • GlobeNewswire

    Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021

    Presentation of five scientific abstracts selected for poster presentations at the AASLD The Liver Meeting™ 2021 by Prof. Nezam Afdhal and Prof. Jörn SchattenbergUpdate on the current NASH landscape by Prof. Nezam AfdhalUpdate on Inventiva’s Phase II clinical trial evaluating lanifibranor in patients with type 2 diabetes (T2D) and non alcoholic fatty liver disease (NAFLD) by Prof. Kenneth CusiPresentation of Inventiva’s Phase IIa combination study with lanifibranor and SGLT2 inhibitor empagliflo

  • GlobeNewswire

    Inventiva announces participation at several conferences in November 2021

    Daix (France), Long Island City (New York, United States), November 29, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company’s leadership will participate in two upcoming conferences in November 2021. The event details are

Advertisement
Advertisement